Dimerix (ASX:DXB) Phase 2 interim data reading should be out soon!
22 February 2024: We spoke with Dr Nina Webster, CEO of Dimerix (ASX: DXB), about the excellent economics behind DMX-200 for Focal Segmental Glomulerosclerosis (FSGS) and the near-term nature of the programme, with the first interim data from the current Phase 2 reading out shortly.
